# Jason Wild

> Jason Wild is a Series A investor at JW Asset Management (Bedford) backing Medical and Cannabis. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [JW Asset Management](https://shizune.co/investors/profile/jw-asset-management)
- Location: Bedford, United States
- Total investments: 8
- Last investment: Jul 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jason-wild-b8a7304/

Jason Wild is a Series A investor at JW Asset Management in Bedford focused on Medical and Cannabis. Jason Wild is the Founder, President and Chief Investment Officer of JW Asset Management, LLC, the advisor for three investment partnerships. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceuticalsector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor’s degree in Pharmacy.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 38% |
| Cannabis | 3 | 38% |
| Pharmaceutical | 3 | 38% |
| Health Care | 2 | 25% |
| SaaS | 1 | 13% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Funding Round | 2 | 25% |
| Pre-Seed | 1 | 13% |
| Series C | 1 | 13% |
| Post-IPO Debt | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 75% |
| Canada | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TerrAscend | TerrAscend is a vertically-integrated Canadian cannabis company that strives to create and deliver quality products and services that meet the evolving needs of the cannabis market. It provides support to patients through its wholly-owned subsidiaries, Solace Health Inc., a licensed producer of cannabis under the Access to Cannabis for MedicalPurposes Regulations, and Terra Health Network Inc., a provider of clinical support and education programs led by health care professionals. TerrAscend offers prescription cannabinoids and medical cannabis solutions for patients suffering from chronic pain and debilitating illnesses and focuses on drug research and development, cannabis devices, delivery systems, and hemp health products. | $57.7M | Post-IPO Debt | Jul 09, 2025 |  |
| InnovationForce | Named a Top 10 "Most Innovative Workplace” solution of 2024 by Fast Company, InnovationForce democratizes innovation with AI-powered solutions that enable ecosystem collaboration and corporate level decision-making to simplify innovation. Our customers make decision 85% faster saving on average $500,000 per idea. By leveraging the “collectivegenius” of crowds and insights from our co-founder, renowned Harvard Business School professor Dr. Linda Hill, the platform has proven it can help leaders solve critical climate and infrastructure challenges faster and smarter. |  | Pre-Seed | Mar 26, 2024 |  |
| Tyson 2.0 | Tyson 2.0 is a cannabis company producing cannabis products known for purity, precision, and wide accessibility. Providing consumers an outstanding selection of products, Tyson 2.0 is an extraordinary balance of premium and affordable, full-spectrum cannabis flower, concentrates, and consumables available at retailers nationwide. The company wasformed by the legendary boxer, entrepreneur, and icon, Mike Tyson. | $9M | Series A | Jun 30, 2022 |  |
| Vensun Pharmaceuticals | Vensun Pharmaceuticals is a pharmaceutical company developing generic prescription products in various dosage forms. As a rapidly emerging generic pharmaceutical company, Vensun has filed several Abbreviated New Drug Applications (ANDAs) with the FDA through its partnerships and currently has over 30 products in active development. We are activelyseeking additional opportunities for partnerships, strategic alliances, and product acquisitions to enhance our existing development portfolio. | $22.5M | Series C | Dec 01, 2016 |  |
| Establishment Labs | Establishment Labs is a medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to thestrictest quality assurance testing throughout the manufacturing process. Motiva Implants are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards. | $15M | Debt Financing | Sep 29, 2016 |  |
| Gage Cannabis | Gage Cannabis Co. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. | $10M |  |  |  |
| Vitruvias Therapeutics | Vitruvias Therapeutics is a start-up generic pharmaceutical company that will focus on developing niche topical generic products that are sold only by prescription. The name of the company is taken from Leonardo da Vinci’s drawing “The Vitruvian Man” which refers to the idealized proportionality of the human figure.The company was founded in 2013and is based in Montgomery, Alabama. | $11.5M | Series A |  |  |
| Establishment Labs | Establishment Labs is a medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to thestrictest quality assurance testing throughout the manufacturing process. Motiva Implants are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards. |  |  |  |  |

8 of 8 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 3 deals together
- [Ambria Capital](https://shizune.co/investors/profile/ambria-capital) — VC Fund, 1 deal together
- [Deerfield Capital Management](https://shizune.co/investors/profile/deerfield-management) — VC Fund, 1 deal together
- [FocusGrowth Asset Management](https://shizune.co/investors/profile/focusgrowth-asset-management) — VC Fund, 1 deal together
- [K2](https://shizune.co/investors/profile/k2) — VC Fund, 1 deal together
- [Relativity](https://shizune.co/investors/profile/relativity-2) — VC Fund, 1 deal together

## About JW Asset Management

VC Fund · New York, United States

JW Asset Management is a New York-based investment firm that primarily invests within the healthcare sector. The company runs 3 Hedge Funds and two Private Equity Funds. It has led the investor group in the 2010 acquisition of Arbor Pharmaceuticals, Inc. and recently as the lead investor in TerrAscend Corp.

2 contacts available at JW Asset Management.

| Name | Title | Profile |
| --- | --- | --- |
| Jason Wild | Founder, President & Chief Investment Officer | https://shizune.co/investors/profile/jason-wild |
| Jason Klarreich | Managing Director, CFO, COO, & CCO | https://shizune.co/investors/profile/jason-klarreich |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jason Wild invest in?

Jason Wild invests primarily in Medical, Cannabis and Pharmaceutical startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jason Wild last invest?

The most recent investment recorded for Jason Wild closed in Jul 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co